Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Spyre Therapeutics, Inc. (SYRE) had Free Cash Flow per Share of $-1.45 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-36.72M |
|
-- |
|
-- |
|
$41.94M |
|
$-41.94M |
|
$5.22M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-36.72M |
|
$-41.94M |
|
$-41.94M |
|
60.33M |
|
60.33M |
|
$-0.49 |
|
$-0.49 |
|
| Balance Sheet Financials | |
$538.83M |
|
-- |
|
-- |
|
$538.83M |
|
$83.06M |
|
-- |
|
-- |
|
$83.06M |
|
$299.95M |
|
$455.77M |
|
$455.77M |
|
60.37M |
|
| Cash Flow Statement Financials | |
$-87.56M |
|
$78.94M |
|
$0.86M |
|
$89.42M |
|
$81.66M |
|
$-7.76M |
|
$18.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.49 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-87.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.24% |
|
-8.06% |
|
-6.81% |
|
-8.06% |
|
$7.55 |
|
|
Free Cash Flow per Share |
$-1.45 |
$-1.45 |
|